RVT-1401
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graves' Ophthalmopathy
Conditions
Graves' Ophthalmopathy
Trial Timeline
Apr 22, 2019 → May 21, 2020
NCT ID
NCT03922321About RVT-1401
RVT-1401 is a phase 2 stage product being developed by Immunovant for Graves' Ophthalmopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT03922321. Target conditions include Graves' Ophthalmopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03922321 | Phase 2 | Completed |
Competing Products
6 competing products in Graves' Ophthalmopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CFZ533 | Novartis | Phase 2 | 52 |
| Rilzabrutinib dose 1 + Rilzabrutinib dose 2 | Sanofi | Phase 2 | 51 |
| IMVT-1402 | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |
| RVT-1401 (Administered via subcutaneous injection) | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |